Windlas Biotech Limited (WINDLAS) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.016x

Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has a cash flow conversion efficiency ratio of 0.016x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs66.60 Million ≈ $720.25K USD) by net assets (Rs4.16 Billion ≈ $45.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Windlas Biotech Limited strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Windlas Biotech Limited - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Windlas Biotech Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. See WINDLAS book value for net asset value and shareholders' equity analysis.

Windlas Biotech Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Windlas Biotech Limited ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
FREYR Battery SA NYSE:FREY	-0.178x
IM Vinaria Purcari SRL RO:WINE	-0.002x
Catella AB (publ) ST:CAT-B	0.009x
LVMC Holdings KO:900140	0.022x
Tachan Securities Co Ltd TWO:6020	-0.043x
Ultra Chip TWO:3141	0.046x
Kumpulan Fima Bhd KLSE:6491	0.047x
Tai-Saw Technology Co Ltd TWO:3221	0.026x

Annual Cash Flow Conversion Efficiency for Windlas Biotech Limited (2018–2025)

The table below shows the annual cash flow conversion efficiency of Windlas Biotech Limited from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see WINDLAS company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	Rs5.06 Billion ≈ $54.70 Million	Rs681.87 Million ≈ $7.37 Million	0.135x	-44.33%
2024-03-31	Rs4.50 Billion ≈ $48.66 Million	Rs1.09 Billion ≈ $11.78 Million	0.242x	+59.79%
2023-03-31	Rs4.02 Billion ≈ $43.50 Million	Rs609.65 Million ≈ $6.59 Million	0.152x	+555.31%
2022-03-31	Rs3.95 Billion ≈ $42.69 Million	Rs91.30 Million ≈ $987.37K	0.023x	-59.80%
2021-03-31	Rs1.99 Billion ≈ $21.53 Million	Rs114.54 Million ≈ $1.24 Million	0.058x	-51.77%
2020-03-31	Rs2.10 Billion ≈ $22.67 Million	Rs250.06 Million ≈ $2.70 Million	0.119x	+23.77%
2019-03-31	Rs1.94 Billion ≈ $20.94 Million	Rs186.54 Million ≈ $2.02 Million	0.096x	-59.28%
2018-03-31	Rs1.25 Billion ≈ $13.52 Million	Rs295.91 Million ≈ $3.20 Million	0.237x	--

About Windlas Biotech Limited

NSE:WINDLAS India Drug Manufacturers - Specialty & Generic

Market Cap

$186.84 Million

Rs17.28 Billion INR

Market Cap Rank

#16896 Global

#871 in India

Share Price

Rs819.70

Change (1 day)

-0.38%

52-Week Range

Rs718.35 - Rs1070.80

All Time High

Rs1144.25